Bi 1994.
Methods | Randomisation: randomised, no further details. Allocation: procedure not described. Blinding: n.i., probably open. Duration: 4 weeks. Design: parallel. Location: n.i.. Setting: n.i.. | |
Participants | Diagnosis: schizophrenia (Research Diagnostic Criteria RDC) and (CCMD‐2, Chinese classification of mental disorders). N = 37. Gender: 24 M, 26 F. Age: 18‐45 years. History: duration stable ‐ n.i., duration ill ‐ n.i., number of previous hospitalisations ‐ n.i., age at onset ‐ n.i., severity of illness ‐ n.i., baseline antipsychotic dose ‐ n.i.. | |
Interventions | 1. Haloperidol: fixed/flexible dose n.i., allowed dose range 5 to 100 mg/day, mean dose n.i.. N = 17. 2. Chlorpromazine: fixed/flexible dose n.i., allowed dose range 50 to 500 mg/day, mean dose n.i.. N = 20. Other medication: n.i.. | |
Outcomes | Response to treatment: BPRS (no clear definition).
Leaving the study early.
Mental state: BPRS. Global state: CGI. Adverse effects: at least one movement disorder, average score change in EPS. |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Randomised, no further details. |
Allocation concealment (selection bias) | Unclear risk | Procedure not described. |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Not indicated, probably open. |
Blinding of outcome assessment (detection bias) All outcomes | High risk | Not indicated, probably open. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Insufficient information to permit judgement about incomplete outcome data. |
Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgment about selective reporting. |
Other bias | Low risk | No clear other bias. |